Search

Your search keyword '"Gonzalez, Michael O."' showing total 40 results
Start Over Author "Gonzalez, Michael O."
40 results on '"Gonzalez, Michael O."'

1. Long-term immune response to SARS-CoV-2 infection and vaccination in children and adolescents

Author

Messiah, Sarah E., Talebi, Yashar, Swartz, Michael D., Sabharwal, Rachit, Han, Haoting, Bergqvist, Emma, Kohl, III, Harold W., Valerio-Shewmaker, Melissa, DeSantis, Stacia M., Yaseen, Ashraf, Kelder, Steven H., Ross, Jessica, Padilla, Lindsay N., Gonzalez, Michael O., Wu, Leqing, Lakey, David, Shuford, Jennifer A., Pont, Stephen J., and Boerwinkle, Eric

Published
2024
Full Text
View/download PDF

2. LIMFAST. I. A Semi-Numerical Tool for Line Intensity Mapping

Author

Mas-Ribas, Lluís, Sun, Guochao, Chang, Tzu-Ching, Gonzalez, Michael O., and Mebane, Richard H.

Subjects
Astrophysics - Cosmology and Nongalactic Astrophysics, Astrophysics - Astrophysics of Galaxies, Astrophysics - Instrumentation and Methods for Astrophysics
Abstract

We present LIMFAST, a semi-numerical code for simulating high-redshift galaxy formation and cosmic reionization as revealed by multi-tracer line intensity mapping (LIM) signals. LIMFAST builds upon and extends the 21cmFAST code widely used for 21 cm cosmology by implementing state-of-the-art models of galaxy formation and evolution. The metagalactic radiation background, including the production of various star-formation lines, together with the 21 cm line signal tracing the neutral intergalactic medium (IGM), are self-consistently described by photoionization modeling and stellar population synthesis coupled to the galaxy formation model. We introduce basic structure and functionalities of the code, and demonstrate its validity and capabilities by showing broad agreements between the predicted and observed evolution of cosmic star formation, IGM neutral fraction, and metal enrichment. We also present the LIM signals of 21 cm, Ly$\alpha$, H$\alpha$, H$\beta$, [OII], and [OIII] lines simulated by LIMFAST, and compare them with results from the literature. We elaborate on how several major aspects of our modeling framework, including models of star formation, chemical enrichment, and photoionization, may impact different LIM observables and thus become testable once applied to observational data. LIMFAST aims at being an efficient and resourceful tool for intensity mapping studies in general, exploring a wide range of scenarios of galaxy evolution and reionization and frequencies over which useful cosmological signals can be measured., Comment: 24 pages, 12 figures; to appear in ApJ after being significantly updated from v1

Published
2022
Full Text
View/download PDF

3. LIMFAST. II. Line Intensity Mapping as a Probe of High-Redshift Galaxy Formation

Author

Sun, Guochao, Mas-Ribas, Lluís, Chang, Tzu-Ching, Furlanetto, Steven R., Mebane, Richard H., Gonzalez, Michael O., Parsons, Jasmine, and Trapp, A. C.

Subjects
Astrophysics - Cosmology and Nongalactic Astrophysics, Astrophysics - Astrophysics of Galaxies, Astrophysics - Instrumentation and Methods for Astrophysics
Abstract

The epoch of reionization (EoR) offers a unique window into the dawn of galaxy formation, through which high-redshift galaxies can be studied by observations of both themselves and their impact on the intergalactic medium. Line intensity mapping (LIM) promises to explore cosmic reionization and its driving sources by measuring intensity fluctuations of emission lines tracing the cosmic gas in varying phases. Using LIMFAST, a novel semi-numerical tool designed to self-consistently simulate LIM signals of multiple EoR probes, we investigate how building blocks of galaxy formation and evolution theory, such as feedback-regulated star formation and chemical enrichment, might be studied with multi-tracer LIM during the EoR. On galaxy scales, we show that the star formation law and the feedback associated with star formation can be indicated by both the shape and redshift evolution of LIM power spectra. For a baseline model of metal production that traces star formation, we find that lines highly sensitive to metallicity are generally better probes of galaxy formation models. On larger scales, we demonstrate that inferring ionized bubble sizes from cross-correlations between tracers of ionized and neutral gas requires a detailed understanding of the astrophysics that shape the line luminosity--halo mass relation. Despite various modeling and observational challenges, wide-area, multi-tracer LIM surveys will provide important high-redshift tests for the fundamentals of galaxy formation theory, especially the interplay between star formation and feedback by accessing statistically the entire low-mass population of galaxies as ideal laboratories, complementary to upcoming surveys of individual sources by new-generation telescopes., Comment: 24 pages, 15 figures; to appear in ApJ

Published
2022
Full Text
View/download PDF

4. Probing Population III Initial Mass Functions with He II/H$\alpha$ Intensity Mapping

Author

Parsons, Jasmine, Mas-Ribas, Lluis, Sun, Guochao, Chang, Tzu-Ching, Gonzalez, Michael O., and Mebane, Richard H.

Subjects
Astrophysics - Astrophysics of Galaxies, Astrophysics - Cosmology and Nongalactic Astrophysics
Abstract

We demonstrate the potential of line-intensity mapping to place constraints on the initial mass function (IMF) of Population III stars via measurements of the mean He II 1640A/H$\alpha$ line-intensity ratio. We extend the 21cmFAST code with modern high-redshift galaxy-formation and photoionization models, and estimate the line emission from Population II and Population III galaxies at redshifts $5 \le z \le 20$. In our models, mean ratio values of He II/H$\alpha \gtrsim 0.1$ indicate top-heavy Population III IMFs with stars of several hundred solar masses, reached at $z \gtrsim 10$ when Population III stars dominate star formation. A next-generation space mission with capabilities moderately superior to those of CDIM will be able to probe this scenario by measuring the He II and H$\alpha$ fluctuation power spectrum signals and their cross-correlation at high significance up to $z\sim 20$. Moreover, regardless of the IMF, a ratio value of He II/H$\alpha \lesssim 0.01$ indicates low Population III star formation and, therefore, it signals the end of the period dominated by this stellar population. However, a detection of the corresponding He II power spectrum may be only possible for top-heavy Population III IMFs or through cross-correlation with the stronger H$\alpha$ signal. Finally, ratio values of $0.01 \lesssim$ He II/H$\alpha$ $\lesssim 0.1$ are complex to interpret because they can be driven by several competing effects. We discuss how various measurements at different redshifts and the combination of the line-intensity ratio with other probes can assist in constraining the Population III IMF in this case., Comment: Updated to match the accepted ApJ version. Main results in Fig.3 and Fig.6

Published
2021
Full Text
View/download PDF

5. Acute respiratory distress syndrome, acute kidney injury, and mortality after trauma are associated with increased circulation of syndecan-1, soluble thrombomodulin, and receptor for advanced glycation end products

Author

Dixon, Alexandra, Kenny, James E., Buzzard, Lydia, Holcomb, John, Bulger, Eileen, Wade, Charles, Fabian, Timothy, Schreiber, Martin, Holcomb, John B., Wade, Charles E., del Junco, Deborah J., Fox, Erin E., Matijevic, Nena, Podbielski, Jeanette M., Beeler, Angela M., Tilley, Barbara C., Baraniuk, Sarah, DeSantis, Stacia M., Zhu, Hongjian, Nixon, Joshua, Seay, Roann, Appana, Savitri N., Yang, Hui, Gonzalez, Michael O., Baer, Lisa, Wang, Yao-Wei Willa, Hula, Brittany S., Espino, Elena, Nguyen, An, Pawelczyk, Nicholas, Arora-Nutall, Kisha D., Sharma, Rishika, Cardenas, Jessica C., Rahbar, Elaheh, Burnett, Tyrone, Jr, Clark, David, van Belle, Gerald, May, Susanne, Leroux, Brian, Hoyt, David, Powell, Judy, Sheehan, Kellie, Hubbard, Alan, Arkin, Adam P., Hess, John R., Callum, Jeannie L., Pittet, Jean-Francois, Miller, Christopher N., Cotton, Bryan A., Vincent, Laura, Welch, Timothy, Poole, Tiffany, Pivalizza, Evan G., Gumbert, Sam D., Bai, Yu, McCarthy, James J., Noland, Amy, Hobbs, Rhonda, Bulger, Eileen M., Klotz, Patricia, Cattin, Lindsay, Warner, Keir J., Wilson, Angela, Boman, David, White, Nathan, Grabinsky, Andreas, Daniel-Johnson, Jennifer A., Cohen, Mitchell Jay, Callcut, Rachael A., Nelson, Mary, Redick, Brittney, Conroy, Amanda, Steurer, Marc P., Maxim, Preston C., Fiebig, Eberhard, Moore, Joanne, Mallari, Eireen, Muskat, Peter, Johannigman, Jay A., Robinson, Bryce R. H., Branson, Richard D., Gomaa, Dina, Barczak, Christopher, Bennett, Suzanne, Carey, Patricia M., Hancock, Helen, Rodriguez, Carolina, Inaba, Kenji, Zhu, Jay G., Wong, Monica D., Menchine, Michael, Katzberg, Kelly, Henderson, Sean O., McKeever, Rodney, Shulman, Ira A., Nelson, Janice M., Tuma, Christopher W., Matsushita, Cheryl Y., Scalea, Thomas M., Stein, Deborah M., Shaffer, Cynthia K., Wade, Christine, Herrera, Anthony V., Kallam, Seeta, Wade, Sarah E., Galvagno, Samuel M., Jr, Fontaine, Magali J., Hunt, Janice M., Cooke, Rhonda K., Fabian, Timothy C., Weinberg, Jordan A., Croce, Martin A., Wilson, Suzanne, Panzer-Baggett, Stephanie, Waddle-Smith, Lynda, Flax, Sherri, Brasel, Karen J., Walsh, Pamela, Milia, David, Nelson, Allia, Kaslow, Olga, Aufderheide, Tom P., Gottschall, Jerome L., Carpenter, Erica, OʼKeeffe, Terence, Rokowski, Laurel L., Denninghoff, Kurt R., Redford, Daniel T., Novak, Deborah J., Knoll, Susan, Kerby, Jeffrey D., Bosarge, Patrick L., Pierce, Albert T., Williams, Carolyn R., Stephens, Shannon W., Wang, Henry E., Marques, Marisa B., Schreiber, Martin A., Watters, Jennifer M., Underwood, Samantha J., Groat, Tahnee, Newgard, Craig, Merkel, Matthias, Scanlan, Richard M., Miller, Beth, Rizoli, Sandro, Tien, Homer, Nascimento, Barto, Trpcic, Sandy, Sobrian-Couroux, Skeeta, Reis, Marciano, Pérez, Adic, Belo, Susan E., Merkley, Lisa, and Colavecchia, Connie

Published
2024
Full Text
View/download PDF

6. Older Blood Is Associated With Increased Mortality and Adverse Events in Massively Transfused Trauma Patients: Secondary Analysis of the PROPPR Trial

Author

Jones, Allison R, Patel, Rakesh P, Marques, Marisa B, Donnelly, John P, Griffin, Russell L, Pittet, Jean-Francois, Kerby, Jeffrey D, Stephens, Shannon W, DeSantis, Stacia M, Hess, John R, Wang, Henry E, Group, PROPPR Study, Holcomb, John B, Wade, Charles E, del Junco, Deborah J, Fox, Erin E, Matijevic, Nena, Podbielski, Jeanette, Beeler, Angela M, Tilley, Barbara C, Baraniuk, Sarah, Zhu, Hongjian, Nixon, Joshua, Seay, Roann, Appana, Savitri N, Yang, Hui, Gonzalez, Michael O, Baer, Lisa, Wang, Yao-Wei W, Hula, Brittany S, Espino, Elena, Nguyen, An, Pawelczyk, Nicholas, Arora-Nutall, Kisha D, Sharma, Rishika, Cardenas, Jessica C, Rahbar, Elaheh, Burnett, Tyrone, Clark, David, van Belle, Gerald, May, Susanne, Leroux, Brian, Hoyt, David, Powell, Judy, Sheehan, Kellie, Hubbard, Alan, Arkin, Adam P, Callum, Jeanne, Cotton, Bryan A, Vincent, Laura, Welch, Timothy, Poole, Tiffany, Pivalizza, Evan G, Gumbert, Sam D, Bai, Yu, McCarthy, James J, Noland, Amy, Hobbs, Rhonda, Bulger, Eileen M, Klotz, Patricia, Cattin, Lindsay, Warner, Keir J, Wilson, Angela, Boman, David, White, Nathan, Grabinsky, Andreas, Daniel-Johnson, Jennifer A, Cohen, Mitchell J, Callcut, Rachael A, Nelson, Mary, Redick, Brittney, Conroy, Amanda, Steurer, Marc P, Maxim, Preston C, Fiebig, Eberhard, Moore, Joanne, Mallari, Eireen, Muskat, Peter, Johannigman, Jay A, Robinson, Bryce RH, Branson, Richard D, Gomaa, Dina, Barczak, Christopher, Bennett, Suzanne, Carey, Patricia M, Miller, Christopher N, Hancock, Helen, Rodriguez, Carolina, Inaba, Kenji, Zhu, Jay G, Wong, Monica D, Menchine, Michael, Katzberg, Kelly, Henderson, Sean O, McKeever, Rodney, Shulman, Ira A, Nelson, Janice M, Tuma, Christopher W, and Matsushita, Cheryl Y

Subjects
Clinical Research, Clinical Trials and Supportive Activities, Hematology, Physical Injury - Accidents and Adverse Effects, Good Health and Well Being, Adult, Blood Preservation, Blood Transfusion, Critical Illness, Female, Hospital Mortality, Humans, Male, Middle Aged, Odds Ratio, Trauma Centers, PROPPR Study Group, Clinical Sciences, Emergency & Critical Care Medicine
Abstract

Study objectiveThe transfusion of older packed RBCs may be harmful in critically ill patients. We seek to determine the association between packed RBC age and mortality among trauma patients requiring massive packed RBC transfusion.MethodsWe analyzed data from the Pragmatic, Randomized Optimal Platelet and Plasma Ratios trial. Subjects in the parent trial included critically injured adult patients admitted to 1 of 12 North American Level I trauma centers who received at least 1 unit of packed RBCs and were predicted to require massive blood transfusion. The primary exposure was volume of packed RBC units transfused during the first 24 hours of hospitalization, stratified by packed RBC age category: 0 to 7 days, 8 to 14 days, 15 to 21 days, and greater than or equal to 22 days. The primary outcome was 24-hour mortality. We evaluated the association between transfused volume of each packed RBC age category and 24-hour survival, using random-effects logistic regression, adjusting for total packed RBC volume, patient age, sex, race, mechanism of injury, Injury Severity Score, Revised Trauma Score, clinical site, and trial treatment group.ResultsThe 678 patients included in the analysis received a total of 8,830 packed RBC units. One hundred patients (14.8%) died within the first 24 hours. On multivariable analysis, the number of packed RBCs greater than or equal to 22 days old was independently associated with increased 24-hour mortality (adjusted odds ratio [OR] 1.05 per packed RBC unit; 95% confidence interval [CI] 1.01 to 1.08): OR 0.97 for 0 to 7 days old (95% CI 0.88 to 1.08), OR 1.04 for 8 to 14 days old (95% CI 0.99 to 1.09), and OR 1.02 for 15 to 21 days old (95% CI 0.98 to 1.06). Results of sensitivity analyses were similar only among patients who received greater than or equal to 10 packed RBC units.ConclusionIncreasing quantities of older packed RBCs are associated with increased likelihood of 24-hour mortality in trauma patients receiving massive packed RBC transfusion (≥10 units), but not in those who receive fewer than 10 units.

Published
2019

7. Onset of Coagulation Function Recovery Is Delayed in Severely Injured Trauma Patients with Venous Thromboembolism

Author

McCully, Belinda H, Connelly, Christopher R, Fair, Kelly A, Holcomb, John B, Fox, Erin E, Wade, Charles E, Bulger, Eileen M, Schreiber, Martin A, Group, PROPPR Study, del Junco, Deborah J, Matijevic, Nena, Podbielski, Jeanette, Beeler, Angela M, Tilley, Barbara C, Baraniuk, Sarah, Nixon, Joshua, Seay, Roann, Appana, Savitri N, Yang, Hui, Gonzalez, Michael O, Baer, Lisa, Wang, Yao-Wei Willa, Hula, Brittany S, Espino, Elena, Nguyen, An, Pawelczyk, Nicholas, Arora-Nutall, Kisha D, Sharma, Rishika, Cardenas, Jessica C, Rahbar, Elaheh, Burnett, Tyrone, Clark, David, van Belle, Gerald, May, Susanne, Leroux, Brian, Hoyt, David, Powell, Judy, Sheehan, Kellie, Hubbard, Alan, Arkin, Adam P, Hess, John R, Callum, Jeanne, Cotton, Bryan A, Vincent, Laura, Welch, Timothy, Poole, Tiffany, Pivalizza, Evan G, Gumbert, Sam D, Bai, Yu, McCarthy, James J, Noland, Amy, Hobbs, Rhonda, Klotz, Patricia, Cattin, Lindsay, Warner, Keir J, Wilson, Angela, Boman, David, White, Nathan, Grabinsky, Andreas, Daniel-Johnson, Jennifer A, Cohen, Mitchell Jay, Callcut, Rachael A, Nelson, Mary, Redick, Brittney, Conroy, Amanda, Steurer, Marc P, Maxim, Preston C, Fiebig, Eberhard, Moore, Joanne, Mallari, Eireen, Muskat, Peter, Johannigman, Jay A, Robinson, Bryce RH, Branson, Richard D, Gomaa, Dina, Barczak, Christopher, Bennett, Suzanne, Carey, Patricia M, Miller, Christopher N, Hancock, Helen, Rodriguez, Carolina, Inaba, Kenji, Zhu, Jay G, Wong, Monica D, Menchine, Michael, Katzberg, Kelly, Henderson, Sean O, McKeever, Rodney, Shulman, Ira A, Nelson, Janice M, Tuma, Christopher W, Matsushita, Cheryl Y, Scalea, Thomas M, Stein, Deborah M, Shaffer, Cynthia K, and Wade, Christine

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Physical Injury - Accidents and Adverse Effects, Hematology, Clinical Research, Cardiovascular, Adult, Anticoagulants, Blood Coagulation Disorders, Blood Coagulation Tests, Female, Humans, Injury Severity Score, Male, Middle Aged, Recovery of Function, Thrombelastography, Trauma Centers, Venous Thromboembolism, Wounds and Injuries, PROPPR Study Group, Surgery, Clinical sciences
Abstract

BackgroundAltered coagulation function after trauma can contribute to development of venous thromboembolism (VTE). Severe trauma impairs coagulation function, but the trajectory for recovery is not known. We hypothesized that enhanced, early recovery of coagulation function increases VTE risk in severely injured trauma patients.Study designSecondary analysis was performed on data from the Pragmatic Randomized Optimal Platelet and Plasma Ratio (PROPPR) trial, excluding patients who died within 24 hours or were on pre-injury anticoagulants. Patient characteristics, adverse outcomes, and parameters of platelet function and coagulation (thromboelastography) were compared from admission to 72 hours between VTE (n = 83) and non-VTE (n = 475) patients. A p value < 0.05 indicates significance.ResultsDespite similar patient demographics, VTE patients exhibited hypercoagulable thromboelastography parameters and enhanced platelet function at admission (p < 0.05). Both groups exhibited hypocoagulable thromboelastography parameters, platelet dysfunction, and suppressed clot lysis (low clot lysis at 30 minutes) 2 hours after admission (p < 0.05). The VTE patients exhibited delayed coagulation recovery (a significant change compared with 2 hours) of K-value (48 vs 24 hours), α-angle (no recovery), maximum amplitude (24 vs 12 hours), and clot lysis at 30 minutes (48 vs 12 hours). Platelet function recovery mediated by arachidonic acid (72 vs 4 hours), ADP (72 vs 12 hours), and collagen (48 vs 12 hours) was delayed in VTE patients. The VTE patients had lower mortality (4% vs 13%; p < 0.05), but fewer hospital-free days (0 days [interquartile range 0 to 8 days] vs 10 days [interquartile range 0 to 20 days]; p < 0.05) and higher complication rates (p < 0.05).ConclusionsRecovery from platelet dysfunction and coagulopathy after severe trauma were delayed in VTE patients. Suppressed clot lysis and compensatory mechanisms associated with altered coagulation that can potentiate VTE formation require additional investigation.

Published
2017

8. Comparison of Persistent Symptoms Following SARS-CoV-2 Infection by Antibody Status in Nonhospitalized Children and Adolescents

Author

Messiah, Sarah E., Hao, Tianyao, DeSantis, Stacia M., Swartz, Michael D., Talebi, Yashar, Kohl, Harold W., III, Zhang, Shiming, Valerio-Shewmaker, Melissa, Yaseen, Ashraf, Kelder, Steven H., Ross, Jessica, Gonzalez, Michael O., Wu, Leqing, Padilla, Lindsay N, Lopez, Kourtney R., Lakey, David, Shuford, Jennifer A., Pont, Stephen J., and Boerwinkle, Eric

Published
2022
Full Text
View/download PDF

9. Factors associated with elevated SARS-CoV-2 immune response in children and adolescents.

Author

Messiah, Sarah E., Abbas, Rhiana, Bergqvist, Emma, Kohl III, Harold W., Swartz, Michael D., Talebi, Yashar, Sabharwal, Rachit, Han, Haoting, Valerio-Shewmaker, Melissa A., DeSantis, Stacia M., Yaseen, Ashraf, Gandhi, Henal A., Amavisca, Ximena Flandes, Ross, Jessica A., Padilla, Lindsay N., Gonzalez, Michael O., Leqing Wu, Silberman, Mark A., Lakey, David, and Shuford, Jennifer A.

Published
2024
Full Text
View/download PDF

10. Older Blood Is Associated With Increased Mortality and Adverse Events in Massively Transfused Trauma Patients: Secondary Analysis of the PROPPR Trial

Author

Holcomb, John B., Wade, Charles E., del Junco, Deborah J., Fox, Erin E., Matijevic, Nena, Podbielski, Jeanette, Beeler, Angela M., Tilley, Barbara C., Baraniuk, Sarah, Zhu, Hongjian, Nixon, Joshua, Seay, Roann, Appana, Savitri N., Yang, Hui, Gonzalez, Michael O., Baer, Lisa, Wang, Yao-Wei W., Hula, Brittany S., Espino, Elena, Nguyen, An, Pawelczyk, Nicholas, Arora-Nutall, Kisha D., Sharma, Rishika, Cardenas, Jessica C., Rahbar, Elaheh, Burnett, Tyrone, Jr., Clark, David, van Belle, Gerald, May, Susanne, Leroux, Brian, Hoyt, David, Powell, Judy, Sheehan, Kellie, Hubbard, Alan, Arkin, Adam P., Hess, John R., Callum, Jeanne, Cotton, Bryan A., Vincent, Laura, Welch, Timothy, Poole, Tiffany, Pivalizza, Evan G., Gumbert, Sam D., Bai, Yu, McCarthy, James J., Noland, Amy, Hobbs, Rhonda, Bulger, Eileen M., Klotz, Patricia, Cattin, Lindsay, Warner, Keir J., Wilson, Angela, Boman, David, White, Nathan, Grabinsky, Andreas, Daniel-Johnson, Jennifer A., Cohen, Mitchell J., Callcut, Rachael A., Nelson, Mary, Redick, Brittney, Conroy, Amanda, Steurer, Marc P., Maxim, Preston C., Fiebig, Eberhard, Moore, Joanne, Mallari, Eireen, Muskat, Peter, Johannigman, Jay A., Robinson, Bryce R.H., Branson, Richard D., Gomaa, Dina, Barczak, Christopher, Bennett, Suzanne, Carey, Patricia M., Miller, Christopher N., Hancock, Helen, Rodriguez, Carolina, Inaba, Kenji, Zhu, Jay G., Wong, Monica D., Menchine, Michael, Katzberg, Kelly, Henderson, Sean O., McKeever, Rodney, Shulman, Ira A., Nelson, Janice M., Tuma, Christopher W., Matsushita, Cheryl Y., Scalea, Thomas M., Stein, Deborah M., Shaffer, Cynthia K., Wade, Christine, Herrera, Anthony V., Kallam, Seeta, Wade, Sarah E., Galvagno, Samuel M., Jr., Fontaine, Magali J., Hunt, Janice M., Cooke, Rhonda K., Fabian, Timothy C., Weinberg, Jordan A., Croce, Martin A., Wilson, Suzanne, Panzer-Baggett, Stephanie, Waddle-Smith, Lynda, Flax, Sherri, Brasel, Karen J., Walsh, Pamela, Milia, David, Nelson, Allia, Kaslow, Olga, Aufderheide, Tom P., Gottschall, Jerome L., Carpenter, Erica, O’Keeffe, Terence, Rokowski, Laurel L., Denninghoff, Kurt R., Redford, Daniel T., Novak, Deborah J., Knoll, Susan, Kerby, Jeffrey D., Pittet, Jean-Francois, Bosarge, Patrick L., Pierce, Albert T., Williams, Carolyn R., Stephens, Shannon W., Wang, Henry E., Marques, Marisa B., Schreiber, Martin A., Watters, Jennifer M., Underwood, Samantha J., Groat, Tahnee, Newgard, Craig, Merkel, Matthias, Scanlan, Richard M., Miller, Beth, Rizoli, Sandro, Tien, Homer, Nascimento, Barto, Trpcic, Sandy, Sobrian-Couroux, Skeeta, Reis, Marciano, Pérez, Adic, Belo, Susan E., Merkley, Lisa, Colavecchia, Connie, Jones, Allison R., Patel, Rakesh P., Donnelly, John P., Griffin, Russell L., and DeSantis, Stacia M.

Published
2019
Full Text
View/download PDF

11. Impact of Mobile Stroke Units on Patients With Large Vessel Occlusion Acute Ischemic Stroke: A Prespecified BEST‐MSU Substudy

Author

Czap, Alexandra L., primary, Alexandrov, Anne W., additional, Nour, May, additional, Yamal, Jose‐Miguel, additional, Wang, Mengxi, additional, Jacob, Asha P., additional, Parker, Stephanie A., additional, Tariq, Muhammad Bilal, additional, Rajan, Suja S., additional, Alexandrov, Andrei V., additional, Jones, William J., additional, Navi, Babak B., additional, Spokoyny, Ilana, additional, Mackey, Jason, additional, Lerario, Mackenzie P., additional, Gonzalez, Michael O., additional, Singh, Noopur, additional, Bowry, Ritvij, additional, and Grotta, James C., additional

Published
2023
Full Text
View/download PDF

12. Long-term immune response to SARS-CoV-2 infection and vaccination in children and adolescents

Author

Messiah, Sarah E., primary, Talebi, Yashar, additional, Swartz, Michael D., additional, Sabharwal, Rachit, additional, Han, Haoting, additional, Bergqvist, Emma, additional, Kohl, Harold W., additional, Valerio-Shewmaker, Melissa, additional, DeSantis, Stacia M., additional, Yaseen, Ashraf, additional, Kelder, Steven H., additional, Ross, Jessica, additional, Padilla, Lindsay N., additional, Gonzalez, Michael O., additional, Wu, Leqing, additional, Lakey, David, additional, Shuford, Jennifer A., additional, Pont, Stephen J., additional, and Boerwinkle, Eric, additional

Published
2023
Full Text
View/download PDF

13. Strokes Averted by Intravenous Thrombolysis: A Secondary Analysis of a Prospective, Multicenter, Controlled Trial of Mobile Stroke Units

Author

Navi, Babak B., primary, Bach, Ivo, additional, Czap, Alexandra L., additional, Wang, Mengxi, additional, Yamal, Jose‐Miguel, additional, Jacob, Asha P., additional, Parker, Stephanie A., additional, Rajan, Suja S., additional, Mir, Saad, additional, Sherman, Carla, additional, Willey, Joshua Z., additional, Saver, Jeffrey L., additional, Gonzalez, Michael O., additional, Singh, Noopur, additional, Jones, William J., additional, Ornelas, David, additional, Gonzales, Nicole R., additional, Alexandrov, Anne W., additional, Alexandrov, Andrei V., additional, Nour, May, additional, Spokoyny, Ilana, additional, Mackey, Jason, additional, Collins, Sarah Q., additional, Silnes, Kelly, additional, Fink, Mathew E., additional, English, Joey, additional, Barazangi, Nobl, additional, Bratina, Patti L., additional, Volpi, Jay, additional, Rao, Chethan P. V., additional, Griffin, Laura, additional, Persse, David, additional, and Grotta, James C., additional

Published
2023
Full Text
View/download PDF

14. Elevated Syndecan-1 after Trauma and Risk of Sepsis: A Secondary Analysis of Patients from the Pragmatic, Randomized Optimal Platelet and Plasma Ratios (PROPPR) Trial

Author

Holcomb, John B., Wade, Charles E, del Junco, Deborah J., Fox, Erin E., Matijevic, Nena, Podbielski, Jeanette, Beeler, Angela M., Tilley, Barbara C., Baraniuk, Sarah, Zhu, Hongjian, Nixon, Joshua, Seay, Roann, Appana, Savitri N., Yang, Hui, Gonzalez, Michael O., Baer, Lisa, Willa Wang, Yao-Wei, Hula, Brittany S., Espino, Elena, Nguyen, An, Pawelczyk, Nicholas, Arora-Nutall, Kisha D., Sharma, Rishika, Cardenas, Jessica C., Rahbar, Elaheh, Burnett, Tyrone, Jr., Clark, David, van Belle, Gerald, May, Susanne, Leroux, Brian, Hoyt, David, Powell, Judy, Sheehan, Kellie, Hubbard, Alan, Arkin, Adam P., Hess, John R., Callum, Jeanne, Cotton, Bryan A., Vincent, Laura, Welch, Timothy, Poole, Tiffany, Pivalizza, Evan G., Gumbert, Sam D., Bai, Yu, McCarthy, James J., Noland, Amy, Hobbs, Rhonda, Bulger, Eileen M., Klotz, Patricia, Cattin, Lindsay, Warner, Keir J., Wilson, Angela, Boman, David, White, Nathan, Grabinsky, Andreas, Daniel-Johnson, Jennifer A., Cohen, Mitchell Jay, Callcut, Rachael A., Nelson, Mary, Redick, Brittney, Conroy, Amanda, Steurer, Marc P., Maxim, Preston C, Fiebig, Eberhard, Moore, Joanne, Mallari, Eireen, Muskat, Peter, Johannigman, Jay A., Robinson, Bryce RH., Branson, Richard D., Gomaa, Dina, Barczak, Christopher, Bennett, Suzanne, Carey, Patricia M., Miller, Christopher N., Hancock, Helen, Rodriguez, Carolina, Inaba, Kenji, Zhu, Jay G., Wong, Monica D., Menchine, Michael, Katzberg, Kelly, Henderson, Sean O., McKeever, Rodney, Shulman, Ira A., Nelson, Janice M., Tuma, Christopher W., Matsushita, Cheryl Y, Scalea, Thomas M., Stein, Deborah M., Shaffer, Cynthia K., Wade, Christine, Herrera, Anthony V., Kallam, Seeta, Wade, Sarah E., Galvagno, Samuel M., Jr., Fontaine, Magali J., Hunt, Janice M., Cooke, Rhonda K., Fabian, Timothy C., Weinberg, Jordan A., Croce, Martin A., Wilson, Suzanne, Panzer-Baggett, Stephanie, Waddle-Smith, Lynda, Flax, Sherri, Brasel, Karen J., Walsh, Pamela, Milia, David, Nelson, Allia, Kaslow, Olga, Aufderheide, Tom P., Gottschall, Jerome L., Carpenter, Erica, O'Keeffe, Terence, Rokowski, Laurel L., Denninghoff, Kurt R., Redford, Daniel T., Novak, Deborah J., Knoll, Susan, Kerby, Jeffrey D., Pittet, Jean-Francois, Bosarge, Patrick L., Pierce, Albert T., Williams, Carolyn R., Stephens, Shannon W., Wang, Henry E., Marques, Marisa B., Schreiber, Martin A., Watters, Jennifer M., Underwood, Samantha J., Groat, Tahnee, Newgard, Craig, Merkel, Matthias, Scanlan, Richard M., Miller, Beth, Rizoli, Sandro, Tien, Homer, Nascimento, Barto, Trpcic, Sandy, Sobrian-Couroux, Skeeta, Reis, Marciano, Pérez, Adic, Belo, Susan E., Merkley, Lisa, Colavecchia, Connie, Wei, Shuyan, Gonzalez Rodriguez, Erika, Chang, Ronald, Kao, Lillian S., and Wade, Charles E.

Published
2018
Full Text
View/download PDF

15. Abnormalities of laboratory coagulation tests versus clinically evident coagulopathic bleeding: results from the prehospital resuscitation on helicopters study (PROHS)

Author

Holcomb, John B., Wade, Charles E., Fox, Erin E., Chang, Ronald, Podbielski, Jeanette M., Tomasek, Jeffrey S., del Junco, Deborah J., Swartz, Michael D., DeSantis, Stacia M., Appana, Savitri N., Greene, Thomas J., Yi, Misung, Gonzalez, Michael O., Baraniuk, Sarah, van Belle, Gerald, Leroux, Brian G., Howard, Carrie L., Haymaker, Amanda, Stein, Deborah M., Scalea, Thomas M., Ayd, Benjamin, Das, Pratik, Herrera, Anthony V., Bulger, Eileen M., Robinson, Bryce R.H., Klotz, Patricia, Minhas, Aniqa, Kerby, Jeffrey D., Melton, Sherry M., Williams, Carolyn R., Stephens, Shannon W., Goodman, Michael, Johannigman, Jay A., McMullan, Jason, Branson, Richard D., Gomaa, Dina, Barczak, Christopher, Schreiber, Martin A., Underwood, Samantha J., Watson, Cheri, Zielinski, Martin D., Stubbs, James R., Headlee, Amy, O'Keeffe, Terence, Rhee, Peter, Rokowski, Laurel L., Santoro, John, Jr, Seach, Andrea, Bradford, David, Fealk, Michelle, Latifi, Fortesa, Inaba, Kenji, Kim, Henry, Chudnofsky, Carl, Wong, Monica D., Goodman, Michael D., Appana, Savitri, Johansson, Pär I., Henriksen, Hanne H., Stensballe, Jakob, and Steinmetz, Jacob

Published
2018
Full Text
View/download PDF

16. Outcomes of patients with pre-existing disability managed by mobile stroke units: A sub-analysis of the BEST-MSU study

Author

Pirlog, Bianca O, primary, Jacob, Asha P, additional, Rajan, Suja S, additional, Yamal, Jose-Miguel, additional, Parker, Stephanie A, additional, Wang, Mengxi, additional, Bowry, Ritvij, additional, Czap, Alexandra, additional, Bratina, Patti L, additional, Gonzalez, Michael O, additional, Singh, Noopur, additional, Zou, Jinhao, additional, Gonzales, Nicole R, additional, Jones, William J, additional, Alexandrov, Anne W, additional, Alexandrov, Andrei V, additional, Navi, Babak B, additional, Nour, May, additional, Spokoyny, Ilana, additional, Mackey, Jason, additional, Silnes, Kelly, additional, Fink, Matthew E, additional, Pisarro Sherman, Carla, additional, Willey, Josh, additional, Saver, Jeffrey L, additional, English, Joey, additional, Barazangi, Nobl, additional, Ornelas, David, additional, Volpi, Jay, additional, PV Rao, Chethan, additional, Griffin, Laura, additional, Persse, David, additional, and Grotta, James C, additional

Published
2023
Full Text
View/download PDF

17. Onset of Coagulation Function Recovery Is Delayed in Severely Injured Trauma Patients with Venous Thromboembolism

Author

Holcomb, John B., Wade, Charles E., del Junco, Deborah J., Fox, Erin E., Matijevic, Nena, Podbielski, Jeanette, Beeler, Angela M., Tilley, Barbara C., Baraniuk, Sarah, Nixon, Joshua, Seay, Roann, Appana, Savitri N., Yang, Hui, Gonzalez, Michael O., Baer, Lisa, Willa Wang, Yao-Wei, Hula, Brittany S., Espino, Elena, Nguyen, An, Pawelczyk, Nicholas, Arora-Nutall, Kisha D., Sharma, Rishika, Cardenas, Jessica C., Rahbar, Elaheh, Burnett, Tyrone, Jr., Clark, David, van Belle, Gerald, May, Susanne, Leroux, Brian, Hoyt, David, Powell, Judy, Sheehan, Kellie, Hubbard, Alan, Arkin, Adam P., Hess, John R., Callum, Jeanne, Cotton, Bryan A., Vincent, Laura, Welch, Timothy, Poole, Tiffany, Pivalizza, Evan G., Gumbert, Sam D., Bai, Yu, McCarthy, James J., Noland, Amy, Hobbs, Rhonda, Bulger, Eileen M., Klotz, Patricia, Cattin, Lindsay, Warner, Keir J., Wilson, Angela, Boman, David, White, Nathan, Grabinsky, Andreas, Daniel-Johnson, Jennifer A., Cohen, Mitchell Jay, Callcut, Rachael A., Nelson, Mary, Redick, Brittney, Conroy, Amanda, Steurer, Marc P., Maxim, Preston C., Fiebig, Eberhard, Moore, Joanne, Mallari, Eireen, Muskat, Peter, Johannigman, Jay A., Robinson, Bryce RH., Branson, Richard D., Gomaa, Dina, Barczak, Christopher, Bennett, Suzanne, Carey, Patricia M., Miller, Christopher N., Hancock, Helen, Rodriguez, Carolina, Inaba, Kenji, Zhu, Jay G., Wong, Monica D., Menchine, Michael, Katzberg, Kelly, Henderson, Sean O., McKeever, Rodney, Shulman, Ira A., Nelson, Janice M., Tuma, Christopher W., Matsushita, Cheryl Y., Scalea, Thomas M., Stein, Deborah M., Shaffer, Cynthia K., Wade, Christine, Herrera, Anthony V., Kallam, Seeta, Wade, Sarah E., Galvagno, Samuel M., Jr., Fontaine, Magali J., Hunt, Janice M., Cooke, Rhonda K., Fabian, Timothy C., Weinberg, Jordan A., Croce, Martin A., Wilson, Suzanne, Panzer-Baggett, Stephanie, Waddle-Smith, Lynda, Flax, Sherri, Brasel, Karen J., Walsh, Pamela, Milia, David, Nelson, Allia, Kaslow, Olga, Aufderheide, Tom P., Gottschall, Jerome L., Carpenter, Erica, O'Keeffe, Terence, Rokowski, Laurel L., Denninghoff, Kurt R., Redford, Daniel T., Novak, Deborah J., Knoll, Susan, Kerby, Jeffrey D., Pittet, Jean-Francois, Bosarge, Patrick L., Pierce, Albert T., Williams, Carolyn R., Stephens, Shannon W., Wang, Henry E., Marques, Marisa B., Schreiber, Martin A., Watters, Jennifer M., Underwood, Samantha J., Groat, Tahnee, Newgard, Craig, Merkel, Matthias, Scanlan, Richard M., Miller, Beth, Rizoli, Sandro, Tien, Homer, Nascimento, Barto, Trpcic, Sandy, Sobrian-Couroux, Skeeta, Reis, Marciano, Pérez, Adic, Belo, Susan E., Merkley, Lisa, Colavecchia, Connie, McCully, Belinda H., Connelly, Christopher R., and Fair, Kelly A.

Published
2017
Full Text
View/download PDF

18. Strokes Averted by Intravenous Thrombolysis: A Secondary Analysis of a Prospective, Multicenter, Controlled Trial of Mobile Stroke Units.

Author

Navi, Babak B., Bach, Ivo, Czap, Alexandra L., Wang, Mengxi, Yamal, Jose‐Miguel, Jacob, Asha P., Parker, Stephanie A., Rajan, Suja S., Mir, Saad, Sherman, Carla, Willey, Joshua Z., Saver, Jeffrey L., Gonzalez, Michael O., Singh, Noopur, Jones, William J., Ornelas, David, Gonzales, Nicole R., Alexandrov, Anne W., Alexandrov, Andrei V., and Nour, May

Subjects
STROKE units, SECONDARY analysis, STROKE, THROMBOLYTIC therapy, BRAIN injuries
Abstract

Objective: This study was undertaken to examine averted stroke in optimized stroke systems. Methods: This secondary analysis of a multicenter trial from 2014 to 2020 compared patients treated by mobile stroke unit (MSU) versus standard management. The analytical cohort consisted of participants with suspected stroke treated with intravenous thrombolysis. The main outcome was a tissue‐defined averted stroke, defined as a final diagnosis of stroke with resolution of presenting symptoms/signs by 24 hours attributed to thrombolysis and no acute infarction/hemorrhage on imaging. An additional outcome was stroke with early symptom resolution, defined as a final diagnosis of stroke with resolution of presenting symptoms/signs by 24 hours attributed to thrombolysis. Results: Among 1,009 patients with a median last known well to thrombolysis time of 87 minutes, 159 (16%) had tissue‐defined averted stroke and 276 (27%) had stroke with early symptom resolution. Compared with standard management, MSU care was associated with more tissue‐defined averted stroke (18% vs 11%, adjusted odds ratio [aOR] = 1.82, 95% confidence interval [CI] = 1.13–2.98) and stroke with early symptom resolution (31% vs 21%, aOR = 1.74, 95% CI = 1.12–2.61). The relationships between thrombolysis treatment time and averted/early recovered stroke appeared nonlinear. Most models indicated increased odds for stroke with early symptom resolution but not tissue‐defined averted stroke with earlier treatment. Additionally, younger age, female gender, hyperlipidemia, lower National Institutes of Health Stroke Scale, lower blood pressure, and no large vessel occlusion were associated with both tissue‐defined averted stroke and stroke with early symptom resolution. Interpretation: In optimized stroke systems, 1 in 4 patients treated with thrombolysis recovered within 24 hours and 1 in 6 had no demonstrable brain injury on imaging. ANN NEUROL 2024;95:347–361 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. SARS-CoV-2 Serostatus and COVID-19 Illness Characteristics by Variant Time Period in Non-Hospitalized Children and Adolescents

Author

Messiah, Sarah E., primary, Swartz, Michael D., additional, Abbas, Rhiana A., additional, Talebi, Yashar, additional, Kohl, Harold W., additional, Valerio-Shewmaker, Melissa, additional, DeSantis, Stacia M., additional, Yaseen, Ashraf, additional, Kelder, Steven H., additional, Ross, Jessica A., additional, Padilla, Lindsay N., additional, Gonzalez, Michael O., additional, Wu, Leqing, additional, Lakey, David, additional, Shuford, Jennifer A., additional, Pont, Stephen J., additional, and Boerwinkle, Eric, additional

Published
2023
Full Text
View/download PDF

22. Abstract WP6: Strokes Averted by Intravenous Thrombolysis: A Secondary Analysis of the BEST-MSU Trial

Author

Bach, Ivo, primary, Czap, Alexandra L, additional, Parker, Stephanie A., additional, Jacob, Asha P, additional, Mir, Saad, additional, Wang, Mengxi, additional, Yamal, Jose-Miguel, additional, Rajan, Suja S, additional, Saver, Jeffrey L, additional, Gonzalez, Michael O., additional, Singh, Noopur, additional, Jones, William, additional, Alexandrov, Anne W, additional, Alexandrov, Andrei V, additional, Nour, May, additional, Spokoyny, Ilana, additional, Mackey, Jason, additional, Fink, Matthew E, additional, English, Joey, additional, Barazangi, Nobl, additional, Volpi, John J, additional, Venkatasubba Rao, Chethan P, additional, Kass, Joseph S, additional, Griffin, Laura J, additional, Persse, David, additional, Grotta, James C, additional, and Navi, Babak B, additional

Published
2023
Full Text
View/download PDF

23. Abstract WMP2: Acute Stroke Treatment In Patients With Pre-exiting Disability: A Secondary Analysis Of The BEST-MSU Trial

Author

Pirlog, Bianca O, primary, Jacob, Asha P, additional, Yamal, Jose-Miguel, additional, Parker, Stephanie, additional, Rajan, Suja S, additional, Bowry, Ritvij, additional, Czap, Alexandra L, additional, Bratina, Patti, additional, Gonzalez, Michael O, additional, Singh, Noopur, additional, Wang, Mengxi, additional, Zou, Jinhao, additional, Gonzales, Nicole R, additional, Jones, William J, additional, Alexandrov, Anne W, additional, Alexandrov, Andrei V, additional, Navi, Babak B, additional, Nour, May, additional, Spokoyny, Ilana, additional, Mackey, Jason S, additional, Fink, Matthew E, additional, Saver, Jeffrey L, additional, English, Joey D, additional, Barazangi, Nobl, additional, Volpi, John J, additional, Rao, Chetan P, additional, Kass, Joseph S, additional, Griffin, Laura, additional, Persse, David, additional, and Grotta, James C, additional

Published
2023
Full Text
View/download PDF

24. sj-docx-1-wso-10.1177_17474930231185471 – Supplemental material for Outcomes of patients with pre-existing disability managed by mobile stroke units: A sub-analysis of the BEST-MSU study

Author

Pirlog, Bianca O, Jacob, Asha P, Rajan, Suja S, Yamal, Jose-Miguel, Parker, Stephanie A, Wang, Mengxi, Bowry, Ritvij, Czap, Alexandra, Bratina, Patti L, Gonzalez, Michael O, Singh, Noopur, Zou, Jinhao, Gonzales, Nicole R, Jones, William J, Alexandrov, Anne W, Alexandrov, Andrei V, Navi, Babak B, Nour, May, Spokoyny, Ilana, Mackey, Jason, Silnes, Kelly, Fink, Matthew E, Pisarro Sherman, Carla, Willey, Josh, Saver, Jeffrey L, English, Joey, Barazangi, Nobl, Ornelas, David, Volpi, Jay, PV Rao, Chethan, Griffin, Laura, Persse, David, and Grotta, James C

Subjects
Neurology and Neuromuscular Diseases, FOS: Clinical medicine, Cardiology, Medicine
Abstract

Supplemental material, sj-docx-1-wso-10.1177_17474930231185471 for Outcomes of patients with pre-existing disability managed by mobile stroke units: A sub-analysis of the BEST-MSU study by Bianca O Pirlog, Asha P Jacob, Suja S Rajan, Jose-Miguel Yamal, Stephanie A Parker, Mengxi Wang, Ritvij Bowry, Alexandra Czap, Patti L Bratina, Michael O Gonzalez, Noopur Singh, Jinhao Zou, Nicole R Gonzales, William J Jones, Anne W Alexandrov, Andrei V Alexandrov, Babak B Navi, May Nour, Ilana Spokoyny, Jason Mackey, Kelly Silnes, Matthew E Fink, Carla Pisarro Sherman, Josh Willey, Jeffrey L Saver, Joey English, Nobl Barazangi, David Ornelas, Jay Volpi, Chethan PV Rao, Laura Griffin, David Persse and James C Grotta in International Journal of Stroke

Published
2023
Full Text
View/download PDF

25. Methodology to estimate natural- and vaccine-induced antibodies to SARS-CoV-2 in a large geographic region

Author

DeSantis, Stacia M., primary, León-Novelo, Luis G., additional, Swartz, Michael D., additional, Yaseen, Ashraf S., additional, Valerio-Shewmaker, Melissa A., additional, Talebi, Yashar, additional, Brito, Frances A., additional, Ross, Jessica A., additional, Kohl, Harold W., additional, Messiah, Sarah E., additional, Kelder, Steve H., additional, Wu, Leqing, additional, Zhang, Shiming, additional, Aguillard, Kimberly A., additional, Gonzalez, Michael O., additional, Omega-Njemnob, Onyinye S., additional, Lakey, David, additional, Shuford, Jennifer A., additional, Pont, Stephen, additional, and Boerwinkle, Eric, additional

Published
2022
Full Text
View/download PDF

27. Durability of SARS-CoV-2 Antibodies From Natural Infection in Children and Adolescents

Author

Messiah, Sarah E., primary, DeSantis, Stacia M., additional, Leon-Novelo, Luis G., additional, Talebi, Yashar, additional, Brito, Frances A., additional, Kohl, Harold W., additional, Valerio-Shewmaker, Melissa A., additional, Ross, Jessica A., additional, Swartz, Michael D., additional, Yaseen, Ashraf, additional, Kelder, Steven H., additional, Zhang, Shiming, additional, Omega-Njemnobi, Onyinye S., additional, Gonzalez, Michael O., additional, Wu, Leqing, additional, Boerwinkle, Eric, additional, Lakey, David L., additional, Shuford, Jennifer A., additional, and Pont, Stephen J., additional

Published
2022
Full Text
View/download PDF

28. Antibody Duration After Infection From SARS-CoV-2 in the Texas Coronavirus Antibody Response Survey

Author

Swartz, Michael D, primary, DeSantis, Stacia M, additional, Yaseen, Ashraf, additional, Brito, Frances A, additional, Valerio-Shewmaker, Melissa A, additional, Messiah, Sarah E, additional, Leon-Novelo, Luis G, additional, Kohl, Harold W, additional, Pinzon-Gomez, Cesar L, additional, Hao, Tianyao, additional, Zhang, Shiming, additional, Talebi, Yashar, additional, Yoo, Joy, additional, Ross, Jessica R, additional, Gonzalez, Michael O, additional, Wu, Leqing, additional, Kelder, Steven H, additional, Silberman, Mark, additional, Tuzo, Samantha, additional, Pont, Stephen J, additional, Shuford, Jennifer A, additional, Lakey, David, additional, and Boerwinkle, Eric, additional

Published
2022
Full Text
View/download PDF

29. Impact of the SARS-CoV-2 Delta Variant Versus Pre-Delta Variants In Non-Hospitalized Children

Author

Messiah, Sarah, primary, Talebi, Yashar, additional, Swartz, Michael D., additional, Brito, Frances, additional, Kohl, III, Harold W., additional, Zhang, Shiming, additional, Valerio-Shewmaker, Melissa A., additional, DeSantis, Stacia M., additional, Yaseen, Ashraf, additional, Kelder, Steven H., additional, Omega-Njemnobi, Onyinye S., additional, Ross, Jessica A., additional, Gonzalez, Michael O., additional, Wu, Lequing, additional, Lakey, David, additional, Shuford, Jennifer A., additional, Pont, Stephen J., additional, and Boerwinkle, Eric, additional

Published
2022
Full Text
View/download PDF

30. Antibody Duration After Infection From SARS-CoV-2 in the Texas Coronavirus Antibody Response Survey.

Author

Swartz, Michael D, DeSantis, Stacia M, Yaseen, Ashraf, Brito, Frances A, Valerio-Shewmaker, Melissa A, Messiah, Sarah E, Leon-Novelo, Luis G, Kohl, Harold W, Pinzon-Gomez, Cesar L, Hao, Tianyao, Zhang, Shiming, Talebi, Yashar, Yoo, Joy, Ross, Jessica R, Gonzalez, Michael O, Wu, Leqing, Kelder, Steven H, Silberman, Mark, Tuzo, Samantha, and Pont, Stephen J

Subjects
SARS-CoV-2, COVID-19 pandemic, ANTIBODY formation
Abstract

Understanding the duration of antibodies to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that causes COVID-19 is important to controlling the current pandemic. Participants from the Texas Coronavirus Antibody Response Survey (Texas CARES) with at least 1 nucleocapsid protein antibody test were selected for a longitudinal analysis of antibody duration. A linear mixed model was fit to data from participants (n = 4553) with 1 to 3 antibody tests over 11 months (1 October 2020 to 16 September 2021), and models fit showed that expected antibody response after COVID-19 infection robustly increases for 100 days postinfection, and predicts individuals may remain antibody positive from natural infection beyond 500 days depending on age, body mass index, smoking or vaping use, and disease severity (hospitalized or not; symptomatic or not). [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

31. Strategies to Estimate Prevalence of SARS-CoV-2 Antibodies in a Texas Vulnerable Population: Results From Phase I of the Texas Coronavirus Antibody Response Survey

Author

Valerio-Shewmaker, Melissa A., primary, DeSantis, Stacia, additional, Swartz, Michael, additional, Yaseen, Ashraf, additional, Gonzalez, Michael O., additional, Kohl, Harold W. III, additional, Kelder, Steven H., additional, Messiah, Sarah E., additional, Aguillard, Kimberly A., additional, Breaux, Camille, additional, Wu, Leqing, additional, Shuford, Jennifer, additional, Pont, Stephen, additional, Lakey, David, additional, and Boerwinkle, Eric, additional

Published
2021
Full Text
View/download PDF

32. Durability of SARS-CoV-2 Antibodies from Natural Infection in Children and Adolescents

Author

Messiah, Sarah E., primary, Brito, Frances, additional, Kohl, Harold W., additional, DeSantis, Stacia, additional, Valerio-Shewmaker, Melissa, additional, Ross, Jessica, additional, Swartz, Michael D., additional, Yaseen, Ashraf, additional, Kelder, Steven H., additional, Zhang, Shiming, additional, Omega-Njemnobi, Onyinye S, additional, Gonzalez, Michael O., additional, Wu, Leqing, additional, Boerwinkle, Eric, additional, Lakey, David, additional, Shuford, Jennifer A., additional, and Pont, Stephen J., additional

Published
2021
Full Text
View/download PDF

33. Estimation of Total Immunity to SARS-CoV-2 in Texas

Author

Desantis, Stacia M., primary, León-Novelo, Luis G., additional, Swartz, Michael D., additional, Yaseen, Ashraf S., additional, Valerio, Melissa A., additional, Brito, Frances A., additional, Ross, Jessica A., additional, Kohl, Harold W., additional, Messiah, Sarah E., additional, Kelder, Steve H., additional, Wu, Leqing, additional, Zhang, Shiming, additional, Aguillard, Kimberly A., additional, Gonzalez, Michael O., additional, Omega-Njemnob, Onyinye S., additional, Breaux, Camille J., additional, Lakey, David L, additional, Shuford, Jennifer A., additional, Pont, Stephen, additional, and Boerwinkle, Eric D, additional

Published
2021
Full Text
View/download PDF

34. Strategies to Estimate Prevalence of SARS-CoV-2 Antibodies in a Texas Vulnerable Population: Results from Phase I of the Texas Coronavirus Antibody REsponse Survey (TX CARES)

Author

Valerio-Shewmaker, Melissa, primary, DeSantis, Stacia, additional, Swartz, Michael, additional, Yaseen, Ashraf, additional, Gonzalez, Michael O., additional, Kohl, Harold W., additional, Kelder, Steven H., additional, Messiah, Sarah E., additional, Aguillard, Kimberly A., additional, Breaux, Camille, additional, Wu, Leqing, additional, Shuford, Jennifer, additional, Pont, Stephen, additional, Lakey, David, additional, and Boerwinkle, Eric, additional

Published
2021
Full Text
View/download PDF

35. Probing Population III IMFs with He II/H$\alpha$ Intensity Mapping

Author

Parsons, Jasmine, Mas-Ribas, Lluis, Sun, Guochao, Chang, Tzu-Ching, Gonzalez, Michael O., Mebane, Richard H., Parsons, Jasmine, Mas-Ribas, Lluis, Sun, Guochao, Chang, Tzu-Ching, Gonzalez, Michael O., and Mebane, Richard H.

Abstract

We demonstrate the potential of line intensity mapping to place constraints on the initial mass function (IMF) of Population III (Pop III) stars via measurements of the mean He II 1640A/H$\alpha$ emission line ratio. We extend the 21cmFAST code with modern high-redshift galaxy formation and photoionization models, and estimate the line emission from Pop II and Pop III galaxies at redshifts $5 \le z \le 20$. In our models, mean ratio values of He II/H$\alpha \gtrsim 0.1$ indicate top-heavy Pop III IMFs with stars of several hundred solar masses, reached at $z \gtrsim 10$ when Pop III stars dominate star formation. A next-generation space mission with capabilities moderately superior to those of CDIM will be able to probe this scenario by measuring the He II and H$\alpha$ fluctuation power spectrum signals and their cross-correlation at high significance up to $z\sim 20$. Moreover, regardless of the IMF, a ratio value of He II/H$\alpha \lesssim 0.01$ indicates low Pop III star formation and, therefore, it signals the end of the period dominated by this stellar population. However, a detection of the corresponding He II power spectrum may be only possible for top-heavy Pop III IMFs or through cross-correlation with the stronger H$\alpha$ signal. Finally, ratio values of $0.01 \lesssim$ He II/H$\alpha$ $\lesssim 0.1$ are complex to interpret because they can be driven by several competing effects. We discuss how various measurements at different redshifts and the combination of the line ratio with other probes can assist in constraining the Pop III IMF in this case., Comment: Main results in Fig.3 and Fig.6

Published
2021

36. Estimated Prevalence of SARS-CoV-2 Antibodies in the Texas Pediatric Population, 2021

Author

Messiah, Sarah, primary, Valerio-Shewmaker, Melissa A., additional, DeSantis, Stacia M., additional, Swartz, Michael D., additional, Yaseen, Ashraf, additional, Brito, Frances A., additional, Kohl, III, Harold W., additional, Kelder, Steven H., additional, Aguillard, Kimberly, additional, Omega-Njemnobi, Onyinye S., additional, Breaux, Camille, additional, Ross, Jessica A., additional, Gonzalez, Michael O., additional, Zhang, Shiming, additional, Wu, Leqing, additional, Lakey, David, additional, Shuford, Jennifer A., additional, Pont, Stephen J., additional, and Boerwinkle, Eric, additional

Published
2021
Full Text
View/download PDF

37. Abnormalities of laboratory coagulation tests versus clinically evident coagulopathic bleeding: results from the prehospital resuscitation on helicopters study (PROHS)

Author

Chang, Ronald, primary, Fox, Erin E., additional, Greene, Thomas J., additional, Swartz, Michael D., additional, DeSantis, Stacia M., additional, Stein, Deborah M., additional, Bulger, Eileen M., additional, Melton, Sherry M., additional, Goodman, Michael D., additional, Schreiber, Martin A., additional, Zielinski, Martin D., additional, O'Keeffe, Terence, additional, Inaba, Kenji, additional, Tomasek, Jeffrey S., additional, Podbielski, Jeanette M., additional, Appana, Savitri, additional, Yi, Misung, additional, Johansson, Pär I., additional, Henriksen, Hanne H., additional, Stensballe, Jakob, additional, Steinmetz, Jacob, additional, Wade, Charles E., additional, Holcomb, John B., additional, Chang, Ronald, additional, del Junco, Deborah J., additional, Appana, Savitri N., additional, Gonzalez, Michael O., additional, Baraniuk, Sarah, additional, van Belle, Gerald, additional, Leroux, Brian G., additional, Howard, Carrie L., additional, Haymaker, Amanda, additional, Scalea, Thomas M., additional, Ayd, Benjamin, additional, Das, Pratik, additional, Herrera, Anthony V., additional, Robinson, Bryce R.H., additional, Klotz, Patricia, additional, Minhas, Aniqa, additional, Kerby, Jeffrey D., additional, Williams, Carolyn R., additional, Stephens, Shannon W., additional, Goodman, Michael, additional, Johannigman, Jay A., additional, McMullan, Jason, additional, Branson, Richard D., additional, Gomaa, Dina, additional, Barczak, Christopher, additional, Underwood, Samantha J., additional, Watson, Cheri, additional, Stubbs, James R., additional, Headlee, Amy, additional, Rhee, Peter, additional, Rokowski, Laurel L., additional, Santoro, John, additional, Seach, Andrea, additional, Bradford, David, additional, Fealk, Michelle, additional, Latifi, Fortesa, additional, Kim, Henry, additional, Chudnofsky, Carl, additional, and Wong, Monica D., additional

Published
2018
Full Text
View/download PDF

38. Benefits of stroke treatment delivered using a mobile stroke unit trial

Author

Yamal, Jose-Miguel, primary, Rajan, Suja S, additional, Parker, Stephanie A, additional, Jacob, Asha P, additional, Gonzalez, Michael O, additional, Gonzales, Nicole R, additional, Bowry, Ritvij, additional, Barreto, Andrew D, additional, Wu, Tzu-Ching, additional, Lairson, David R, additional, Persse, David, additional, Tilley, Barbara C, additional, Chiu, David, additional, Suarez, Jose I, additional, Jones, William J, additional, Alexandrov, Andrei, additional, and Grotta, James C, additional

Published
2017
Full Text
View/download PDF

39. Benefits of stroke treatment delivered using a mobile stroke unit trial.

Author

Yamal, Jose-Miguel, Rajan, Suja S., Parker, Stephanie A., Jacob, Asha P., Gonzalez, Michael O., Gonzales, Nicole R., Bowry, Ritvij, Barreto, Andrew D., Wu, Tzu-Ching, Lairson, David R., Persse, David, Tilley, Barbara C., Chiu, David, Suarez, Jose I., Jones, William J., Alexandrov, Andrei, and Grotta, James C.

Subjects
ISCHEMIA treatment, STROKE treatment, PLASMINOGEN activators, QUALITY of life, STROKE patients
Abstract

Rationale Mobile stroke units speed treatment for acute ischemic stroke, thereby possibly improving outcomes. Aim To compare mobile stroke unit and standard management clinical outcomes, healthcare utilization, and cost-effectiveness in tissue plasminogen activator-eligible acute ischemic stroke patients calling 911. Sample size 693. Eighty percent power with 0.05 type I error rate to detect a difference of 0.09 in mean utility-weighted modified Rankin scale between groups. Design Phase III, multicenter, prospective cluster-randomized (mobile stroke unit versus standard management weeks) comparative effectiveness study in tissue plasminogen activator-eligible patients. Outcomes Primary: Ninety-day mean utility-weighted modified Rankin scale. Coprimary: cost-effectiveness based on EQ5D quality of life and one year poststroke costs. Analysis Two-sample t-test and linear regression adjusting for covariates; incremental cost-effectiveness ratio and net benefit regression. Results As of March 2017, 288 tissue plasminogen activator-eligible patients have been enrolled (173 in the mobile stroke unit arm and 115 in the standard management arm). Two new centers start in early 2017 with target end of recruitment September 2019. Conclusion This is the first randomized study to test for disability, healthcare utilization, and cost-effectiveness of a mobile stroke unit. The progress of the study suggests that it is feasible. Management of tissue plasminogen activator eligible acute ischemic stroke patients by a mobile stroke unit could potentially result in less disability and healthcare utilization, and be cost effective. Mobile stroke units are very costly. This trial may determine if the fixed cost can be justified by a reduction in disability and healthcare utilization. Clinical Trial Registration NCT02190500. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

40. A Prospective Multicenter Analysis of Mobile Stroke Unit Cost‐Effectiveness.

Author

Rajan, Suja S., Yamal, Jose‐Miguel, Wang, Mengxi, Saver, Jeffrey L., Jacob, Asha P., Gonzales, Nicole R., Ifejika, Nneka, Parker, Stephanie A., Ganey, Christopher, Gonzalez, Michael O., Lairson, David R., Bratina, Patti L., Jones, William J., Mackey, Jason S., Lerario, Mackenzie P., Navi, Babak B., Alexandrov, Ann W., Alexandrov, Andrei, Nour, May, and Spokoyny, Ilana

Subjects
*STROKE units, *TISSUE plasminogen activator, *ISCHEMIC stroke, *MEDICARE reimbursement, *EMERGENCY medical services
Abstract

Objective Methods Results Interpretation Given the high disease and cost burden of ischemic stroke, evaluating the clinical efficacy and cost‐effectiveness of new approaches to prevent and treat ischemic stroke is critical. Effective ischemic stroke management depends on timely administration of thrombolytics after stroke onset. This study evaluates the cost‐effectiveness associated with the use of mobile stroke units (MSUs) to expedite tissue plasminogen activator (tPA) administration, as compared with standard management through emergency medical services (EMS).This study is a prospective, multicenter, alternating‐week, cluster‐controlled trial of MSU versus EMS. One‐year and life‐time cost‐effectiveness analyses, using the incremental cost‐effectiveness ratio (ICER) method, were performed from the perspective of CMS's Medicare. Quality‐adjusted life years (QALYs) estimated using patient‐reported EQ‐5D‐5L data were used as the effectiveness measure. Health care utilizations were converted to costs using average national Medicare reimbursements. ICERs excluding patients with pre‐existing disability, and limited to stroke‐related costs were also calculated.The first‐year ICER for all tPA‐eligible patients using total cost differences between MSU and EMS groups was $238,873/QALY; for patients without pre‐existing disability was $61,199/QALY. The lifetime ICERs for all tPA‐eligible patients and for those without pre‐existing disability were $94,710 and $31,259/QALY, respectively. All ICERs were lower when restricted to stroke‐related costs and were highly dependent on the number of patients treated per year in an MSU.MSUs' cost‐effectiveness is borderline if we consider total first‐year costs and outcomes in all tPA‐eligible patients. MSUs are cost‐effective to highly cost‐effective when calculations are based on patients without pre‐existing disability, patients' lifetime horizon, stroke‐related costs, and more patients treated per year in an MSU. ANN NEUROL 2024 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results